Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A8VU
|
|||
| Drug Name |
PMID29334795-Compound-58
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H31NO
|
|||
| Canonical SMILES |
C1CCC(C1)C(C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4)O
|
|||
| InChI |
1S/C22H31NO/c24-22(19-4-1-2-5-19)20-10-8-17(9-11-20)16-18-12-14-23(15-13-18)21-6-3-7-21/h8-11,16,19,21-22,24H,1-7,12-15H2
|
|||
| InChIKey |
UWSZCEKCJNGAAH-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | . | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.